ANAB

ANAPTYSBIO, INC

CIK: 0001370053

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 13, 2026

AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.

this person other insiders at ANAB

Transaction History

ANAB▼ Sell—

We use analytics to understand how market-wall is used. No personal data is sold.